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Dichloroacetate (DCA) can reverse the glycolytic phenotype in cancer cells that is responsible of increased 
lactate production and extracellular pH acidification. We examined whether MRI-CEST pH mapping can 
monitor in vivo tumour acidosis to assess treatment response to DCA.  
Methods 
Cell viability and extracellular pH were assessed in TS/A breast cancer cells treated with 1-10 mM DCA for 
24 h in normoxia or hypoxia (1% O2) conditions. Extracellular tumour pH values were measured in vivo by 
MRI-CEST pH mapping of TS/A tumour bearing mice before, three days and fifteen days after DCA or 
saline treatment. 
Results 
Reduced extracellular acidification and viability was observed in DCA-treated TS/A cells. Tumour bearing 
mice showed a marked and significant increase of tumour extracellular pH at 3 days post DCA treatment, 
reflecting DCA-induced glycolysis inhibition, as confirmed by reduced lactate production. After 15 days of 
DCA treatment, the onset of resistance to DCA was observed, with recover of tumour extracellular 
acidification and lactate levels that returned to control values. A significant correlation was observed 
between the tumour extracellular pH and lactate levels (r=-0.97, P<0.05). 
Conclusions 
MRI-CEST pH imaging appears a promising tool to monitor the early response and efficacy of cancer 
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It is well known that the extracellular pH (pHe) within the microenvironment of tumours is significantly 
lower (more acidic) compared with that of normal tissues (Gerweck & Seetharaman, 1996). Although several 
factors play a role in this acidification, it is well accepted that the major contribution arises from a shift in the 
ATP generation from oxidative phosphorylation to aerobic glycolysis, even under normal oxygen 
concentrations (Warburg et al, 1927). In this contest, poor vascularisation and increased activity of plasma 
membrane ion pumps and transporters (H+-ATPases, the Na+–H+ exchanger NHE1 and the 
monocarboxylate–H+ efflux co-transporters MCT1 and MCT4) (Webb et al, 2011) contribute to the 
extracellular acidification of most, but not all tumours. Many studies on solid tumours and in particular on 
breast tumours suggested that a glycolytic environment is associated with an antiapoptotic, pro-proliferative 
state and that lactic acidosis facilitates the breakdown of the extra-cellular matrix allowing expansion, 
increase of the metastatic potential and promotion of angiogenesis (Hashim et al, 2011). Therefore, novel 
drugs addressing specific aspects of the deregulated tumour metabolism have been proposed for inhibiting 
tumour growth and survival (Kinnaird & Michelakis, 2015).  
Dichloroacetate (DCA), a mitochondria-targeting small molecule of 150 Da (Michelakis et al, 2008) used to 
treat patients with lactic acidosis, can reverse this cancer-specific metabolic remodelling. DCA inhibits 
pyruvate dehydrogenase kinase (PDK) whose expression is high in many cancers (McFate et al, 2008). PDK 
is a negative regulator of the pyruvate dehydrogenase complex (PDH) that catalyses oxidative 
decarboxylation of pyruvate to acetyl-CoA, which allows the entry of pyruvate into the tricarboxylic acid 
cycle (TCA or Krebs cycle) and away from lactate production. Therefore, PDK leads to an increased lactate 
production. DCA-mediated inhibition of PDK leads to the activation of PDH, increased metabolism of 
pyruvate to acetyl-CoA and decreased lactate production. Thus, DCA increases glucose oxidation promoting 
apoptosis and blocking tumour proliferation (Bonnet et al, 2007). Several clinical studies tested the DCA 
anti-tumour efficacy and its safety in patients with advanced solid tumours (Chu et al, 2015; Dunbar et al, 
2014; Garon et al, 2014). Overall these studies reported that oral DCA is well tolerated and safe, it reduces 
lactate levels and it can act as an apoptosis sensitizer in combination with cytotoxic treatments. 
Despite the specific mechanism of action of DCA on tumour glycolysis, tumour response to DCA treatment 
has conventionally been assessed through simple measurements of changes in tumour size using 
morphological imaging techniques such as Computed Tomography (CT) or Magnetic Resonance Imaging 
(MRI). However, the assessment of changes in tumour volume does not provide indications on variations in 
tumour acidosis induced by metabolism-targeting drugs. Several MRI methods have been proposed for non-
invasive measurements of in vivo tumour pH (Zhang et al, 2010). In particular, 31P-magnetic resonance 
spectroscopy (31P-MRS) allows measuring intracellular pH (pHi) from the chemical shift of endogenous 
phosphate and pHe from the chemical shift of exogenous indicators, such as 3-aminopropyl phosphonate (3-
APP), but with poor spatial resolution (Gillies et al, 1994). Gd-based contrast agents that exhibit a pH-
dependent relaxivity have been exploited for measuring tumour pH in a rat glioma model, but a limitation of 
this approach is related to the need of injecting two Gd-based contrast agents for accurate pH measurements 
(Garcia-Martin et al, 2006). Hyperpolarized 13C bicarbonate can provide pHe map with high sensitivity 
(Gallagher et al, 2008), while several hyperpolarised molecules can provide insight into metabolism in both 
cells and animals (Reineri et al, 2015; Reineri et al, 2016; Serrao & Brindle, 2016; Viale et al, 2012). 
However, this technique is expensive, limited by low spatial resolution and requires sophisticated 
instrumentations that are not easily available in clinical setting. 
Recently, Chemical Exchange Saturation Transfer (CEST) imaging has been proposed as a novel MRI-based 
technique and several pH-responsive agents have been considered for assessing tumour pHe (Hingorani et al, 
2015). Among them, clinical approved radiographic contrast agents have been exploited for measuring pH 
and pathological-induced pH changes (Chen et al, 2014; Chen et al, 2015; Jones et al, 2015; Longo et al, 
2013; Longo et al, 2011; Moon et al, 2015). In  addition, MRI-CEST pH mapping was demonstrated to be an 
excellent tool to investigate the relationship between glycolysis and acidosis at clinical magnetic field 
(Longo et al, 2016a). 
In this study, we investigated MRI-CEST pH mapping as a potential non-invasive biomarker of response 
following DCA treatment, evaluating changes in tumour acidosis in a murine breast cancer model. 
 
 
Materials and Methods  
In Vitro experiments 
Cell culture 
TS/A cells, derived from a spontaneous BALB/c mammary tumour (Nanni et al, 1983), were grown in RPMI 
1640 medium supplemented with 10% fetal bovine serum (FBS), 100U/mL Penicillin and 100 µg/mL 
Streptomycin (Pen/Strep) and 2 mM L-Glutamine. 4T1 cells were purchased from American Type Culture 
Collection, ATCC and cultured as TS/A cells. TUBO cells are derived from a lobular carcinoma arising 
spontaneously in a BALB-neuT mouse (Lanzardo et al, 2016) and were grown in DMEM medium 
supplemented with 20% FBS and Pen/Strep.  
J774 non-tumour cell line (purchased from ATCC) was grown in DMEM medium supplemented with 10% 
FBS, Pen/Strep and L-Glutamine. All the cell lines were cultured at 37 °C in a humidified atmosphere with 
5% CO2 . 
 
Cell viability test 
The cytotoxic effect of DCA (Sigma Aldrich, MO, USA) on cells was analysed with the CellTiter-Blue Cell 
Viability Assay (Promega Corporation, USA). Briefly, TS/A (5 x 103) cells were plated in 96-well culture 
plates and after 24 hours of incubation were treated with DCA (1mM, 5mM and 10mM) for 24 hours. The 
non-tumour cell line J774 (30 x 103) was used as control and treated in the same way. Afterwards, cells were 
washed with PBS and then CellTiter-Blue reagent was added to each well. Fluorescence was measured at 
560Ex/590Em using a 96-well plate reader. Each assay was repeated at least three times. 
 
pH measurement in normoxia and hypoxia condition  
TS/A cells were seeded in culture plates at a density of 4 x 105 cells. After 24 hours of incubator in 20% O2 
(normoxia) or 1% O2 (hypoxia) (New Brunswick™ Galaxy® 48 R, Eppendorf S.r.l., Italy) cells were treated 
with a solution of DCA (1mM, 5mM and 10mM) and let in the culture medium for additional 24 hours. Then 
the culture medium was collected and immediately the pH was measured using a pH meter (Hamilton® Slim 
Trode, GR, Switzerland) previously calibrated. The non-tumour cell line J774 underwent the same 
procedure. Each experiment was performed in triplicate. 
 
FACS analysis  
The cell cycle perturbations were analysed by Propidium Iodide (PI) DNA staining. TS/A cells (5x 105) were 
treated with DCA (1mM, 5mM and 10mM) for 24 hours. At the end of each treatment, cells were collected 
after a centrifugation at 1100 rpm for 5 minutes and then fixed in 70% ethanol for 3 minutes at 4°C. Ethanol-
suspended cells were diluted with phosphate buffered saline (PBS) and then centrifuged at 1500 rpm for 5 
minutes to remove residual ethanol. For cell cycle analysis, the pellets were suspended in 0.1mL of PBS 
containing 50 µg/mL of PI, 100μg/mL of RNase A and 0.05% of Triton X-100 and incubated at 37°C for 40 
minutes. Cell cycle profiles were studied using a CyanADP flow cytometer and analysed with Summit 3.4 
software (Beckman Coulter). Each assay was repeated a minimum of three times. 
 
In Vivo experiments 
Animal experiments  
BALB/c female mice (Charles River Laboratories Italia S.r.l., Calco Italia) were maintained under specific 
pathogen free conditions in the animal facility of the Molecular Biotechnology Center, University of Turin, 
and treated in accordance with the University Ethical Committee and European guidelines under directive 
2010/63.   
Mice were inoculated subcutaneously with 2.5 × 105 TS/A mammary adenocarcinoma cells on both flanks. 
When the tumours were approximately 60mm3, TS/A tumour bearing mice were randomly divided in two 
groups: untreated group that received drinking water and intraperitoneal injections of PBS, and DCA-treated 
group that received DCA by oral administration of 0.45g/L (100mg/Kg day) and also by intraperitoneal 
injections of 50g/L (200mg/Kg/day) (Sun et al, 2010). DCA or PBS solutions were administered every day 
after baseline measurements. All mice were scanned at day 0 (untreated n=10 mice, treated n=8 mice), 3 
days (untreated n=10 mice, treated n=8 mice) and 15 days (untreated n=7 mice, treated n=5 mice) post 
treatment. At each time point post treatment, three mice per group were sacrificed and tumour tissues were 
excised for lactate level quantification. 
For MRI acquisition mice were anesthetized by injecting a mixture of tiletamine/zolazepam (Zoletil 100; 
Virbac, Milan, Italy) 20 mg/kg and xylazine (Rompun; Bayer, Milan, Italy) 5 mg/kg. Breath rate was 
monitored by an air pillow placed below the animal (SA Instruments, Stony Brook, NY; USA). MRI-CEST 
pH mapping was performed upon i.v. injection of iopamidol (Bracco Imaging SpA, Colleretto Giacosa, Italy) 
into the tail vein at a dose of 4g I/kg b.w. through a 27-gauge needle. 
 
MRI CEST pH-mapping acquisition and analysis  
MR images were acquired with a Bruker 7T Avance 300 MRI scanner (BrukerBiospin, Ettlingen, Germany) 
equipped with a 30mm 1H birdcage coil before starting the treatment, after 3 and 15 days of treatment.  
After the scout image acquisition, T2w anatomical images were acquired with a Fast Spin Echo sequence and 
the same geometry was used for the following CEST experiments. CEST images were acquired with a single 
shot FSE sequence with centric encoding preceded by a CW-RF saturation pulse (3μT x 5s) with high in-
plane resolution of 234 µm (FOV 3 cm, MTX 128, slice thickness 1.5mm). Z-spectra were acquired before 
and after iopamidol i.v.injection.  
CEST images were analysed using homemade scripts implemented in MATLAB (The Mathworks, Inc, 
Natick, MA) as previously described (Terreno et al, 2009). Briefly, Saturation Transfer effects were 
calculated upon irradiating at 4.2 and at 5.5 ppm, respectively, and post-contrast ST maps were subtracted to 
pre-contrast ST ones, to obtain the corresponding ST contrast difference (ΔST) maps. The pixel-by-pixel 
extracellular pH maps were calculated using the ratio between the two contrast difference maps at 4.2 and 
5.5 ppm according to the previously described method (Longo et al, 2011).The extracellular pH maps were 
superimposed to the anatomical reference image. 
The heterogeneity of pHe distribution values within the tumour tissue was assessed by calculating the acidity 
score. The pHe values were clustered into three groups: group I consist of pixels showing pHe values > 7.0, 
group II of pixels showing pHe values > 6.7 and < 7.0, group III of pixels showing pHe values < 6.7. The 
percentage of pixels of each group was multiplied by a factor between 1 and 3, to obtain the acidity score, in 
accordance to the equation: 
 
Acidity Score= 	1 × (%	 	 ℎ > 7.0)] +  2 × (%  ℎ 6.7<  < 7.0)]  + 	3 × (%  ℎ < 6.7)]  
 
The acidity score can range between 1 (less acidic) to 3 (more acidic).  
Survival curves 
Female BALB/c mice were inoculated with 2.5 × 105 TS/A cells into the right flank. After the tumour 
reached 1mm diameter, animals were randomized into two groups: untreated (n=9 mice) and DCA-treated 
(n=11 mice). DCA-treated group received DCA by oral administration (100 mg/Kg/day) and also by 
intraperitoneal injection (200 mg/Kg/day) every day. Untreated group received equal volumes of PBS. Mice 
were monitored every other day and volumes were measured using a calibre and calculated from orthogonal 
measurements of external dimensions as [( ℎ − 0.7)2 ×	( ℎ − 0.7)2]/2. Mice were euthanized 
when tumour volume reached values around 600mm3. 
 
Ex Vivo experiments  
Lactate Assay  
After MRI acquisition, three mice per each time point and group were sacrificed and tumour tissues were 
excised and frozen in liquid nitrogen. Tumours were assayed for lactate levels using a Lactate Assay Kit 
(MAK064 Sigma Aldrich, MO, USA) that determined the lactate concentration by an enzymatic reaction. 
Lactate concentration inside the homogenised tumour was determined measuring the absorbance at 570nm 
according to the manufacturer’s instructions. 
 
Statistical analysis  
Calculations were performed using GraphPad Prism (GraphPad Software, La Jolla, CA, USA) software 
package; one-way analysis of variance was used to determine significance among groups, after which post-
hoc tests with the Dunnett's Multiple Comparison Test were used for comparisons between DCA-treated and 
control groups. Correlation analysis were performed using Pearson’s r correlation coefficient.  Data are 
presented as mean ± SD unless otherwise stated. Statistical significance was established at P < 0.05. 
 
Results 
In Vitro experiments 
Cell viability test  
In order to investigate the metabolic inhibition efficiency of DCA, a panel of breast cancer cell lines were 
treated with 1, 5 and 10mM of DCA (Figure1 and Supplementary 1). After 24 hours of treatment under 
normoxia incubation condition, all the cancer cell lines showed a reduction in their metabolic capacity. At 
1mM of DCA, TS/A, TUBO and 4T1 showed a 80%-99% of vitality compared to the untreated cells; at 
5mM of DCA, TUBO and 4T1 showed a 70-90 % of vitality, while TS/A showed a 63% of vitality compared 
to untreated cells. At 10mM of DCA, TUBO and 4T1 showed a 75% of vitality, whereas TS/A cells yielded 
a 58% of vitality compared to untreated cells. The response of TS/A breast cancer after 24 hour of DCA 
treatment was dose-dependent (Figure 1A) and significant reduction of cell vitality was already observed at 
the DCA concentration of 5mM. In contrast, DCA had no effect on the growth of a non-tumour control cell 
line, J774 (Figure 1B). On the basis of these observations, TS/A cell line was selected for subsequent studies 
for its higher response to the DCA treatment. 
 
FACS analysis 
In order to get more insight into how DCA affects cancer cell cycle, TS/A cells were incubated with DCA 
for 24 hours, then stained with PI and analysed by flow cytometry. DCA did not show to affect the cell cycle 
of TS/A cells into a statistically relevant extent, as the amount of cells in the G1/G0 phase decreased from 
51.6%  (untreated cells) to 45.9% in the presence of 10mM DCA (Supplementary Figure 2A, B). The amount 
of TS/A cells in the S phase did not change between untreated and treated with 10mM of DCA 
(Supplementary Figure 2A, C), while cells in phase G2/M increased from 18.8% (untreated cells) to 23.1% 
(Supplementary Figure 2A, D). 
 
pH measurements in normoxia and hypoxia conditions 
The TS/A cells were incubated in the presence of 1, 5 and 10mM of DCA for 24 hours, in both normoxic and 
hypoxic conditions (Figure 1C and 1D). In normoxic condition a moderate but significant and constant 
increase of pHe (from 7.05 to 7.24) was observed upon increasing DCA concentrations. The increase of 
tumour pHe was significantly more pronounced in the hypoxic condition than in the normoxic condition. 
Hypoxic condition resulted in lower pH of the culture medium for TS/A untreated cells in comparison to 
normoxic conditions (pHe=6.75 ± 0,02 and pHe=7.05 ± 0,015 for untreated and treated cells, respectively). 
DCA treatment resulted in a marked increase of pHe from 6.96 to 7.53 (P<0,0001). 
 
In Vivo experiments 
Tumour growth assessment 
The in vivo antitumour activity of DCA was evaluated by measuring the tumour volume in a group of TS/A 
tumour bearing BALB/c mice that received drinking water and PBS intraperitoneal injection (untreated) or 
that were treated with DCA by oral administration and intraperitoneal injection every day for 3 or 15 
consecutive days (Figure 2A). The tumour volume was normalised by dividing the tumour volume post-
treatment to the tumour volume pre-treatment.  DCA treatment slightly reduced the growth of TS/A breast 
tumours after three days of treatment (ΔVolume% = 70.7 ± 38.6 and 83.1 ± 15.7, for treated and untreated 
mice, respectively; P > 0.05). This limited growth reduction is maintained up to 15 days of DCA treatment 
(ΔVolume% = 571.9 ± 180.7 and 646.7 ± 184.0, for untreated and treated mice, respectively; P > 0.05) 
(Figure 2B).  
 
Survival curves 
Intraperitoneal and oral treatments with DCA started when tumour mean volumes where ca. 60 mm3 and 
terminated when tumours reached 600 mm3 in size. DCA-treated mice survived slightly longer then the 
untreated mice (Figure 2C), despite not statistically significant. 
 
MRI CEST pH-mapping 
The pH-responsive contrast agent, upon extravasation inside the tumour region, allowed investigating the 
tumour pHe. A significant pHe increase was observed for treated mice in comparison to untreated ones after 
three days of DCA treatment (ΔpHe= +0.10 and -0.12 for treated and untreated, respectively, P < 0.05). The 
opposite pHe variations were maintained also after 15 days of treatment, despite less marked (ΔpHe= +0.003 
and -0.09 for treated and untreated, respectively, Figure 3A). Representative MRI-CEST pHe images 
overimposed to anatomical images are shown in Figure 4 for treated and untreated mice. Following DCA-
treatment, an increase of the number of pixels with pHe values close to 7-7.4 pH unit is visible, in contrast to 
untreated mice at both the investigated time points (i.e. after 3 and 15 days of DCA treatment). 
To assess more precisely the heterogeneity of the extracellular pH distribution inside the tumour region, it 
was deemed of interest to calculate an index of acidosis (the acidity score). A marked and statistically 
significant difference was observed in the difference of the acidity scores between untreated and treated mice 
after 3 days of treatment (Δacidity score = -0.14 ± 0.23 and +0.15 ± 0.34, P < 0.005, Figure 3B). After 15 
days a marked difference in pHe distribution still remains between treated and untreated mice (Δacidity score 
= 0.003 ± 0.24 and 0.18 ± 0.35 for treated and untreated mice, respectively; P > 0.05). Representative acidity 
score maps are shown in Figure 5 for treated and untreated mice. Upon DCA-treatment, an increase in the 
number of pixels clustered around neutral pH values (colour coded in blue) is well detected after three days 
of treatment. Conversely, untreated mice show an increase of pixels clustered at more acidic values (colour 
coded in red). 
 
Ex Vivo experiments 
Lactate Assay  
The tumour lactate concentration was assessed in TS/A tumour extracts. When TS/A tumour bearing mice 
were treated with oral and intraperitoneal DCA administration for 3 consecutive days, the lactate 
concentration in treated mice was significantly decreased compared with untreated ones (lactate level in 
treated mice is ca. 3 time lower than in untreated mice, P = 0.0077). No significant variation in tumour 
lactate levels was observed comparing treated to untreated mice after 15 days (Figure 3C). A strong and 
significant inverse correlation was found between lactate levels and changes in tumour pHe (Pearson’s r=-
0.97, P < 0.05, Figure 3D); 
 
Discussion 
High rate of glucose uptake and of lactate production are two distinctive features of metabolically altered 
tumour cells. DCA is able to revert the glycolytic phenotype through metabolic inhibition of PDK that allows 
pyruvate to enter into the tricarboxylic acid cycle thus limiting lactate production and in turn, a decrease of 
H+ ions pumped out in the extracellular space. Herein, we investigated the effect of DCA on the tumour pHe 
using the MRI-CEST pH imaging approach. 
First of all, the in vitro sensitivity of different breast cancer cell lines to DCA was assessed. All cancer cell 
lines showed a reduction in their metabolic capacity. The TS/A cell line, that showed a dose-dependent 
response, was selected for further in vivo studies. Interestingly J774, a non-cancerous cell line, was not 
affected by the presence of DCA in the incubation medium, showing that DCA selectively targets cancer 
cells. In previous studies other breast cancer cell lines were treated with DCA (Duan et al, 2013; Sun et al, 
2010). Evidences confirmed that the DCA effect on cell cycle is cellular-dependent (Wong et al, 2008) and 
studies conducted on colon rectal cancer cells revealed that DCA treatment at 20mM concentration caused 
apoptosis and G2 phase cell-cycle arrest (Madhok et al, 2010). We observed a similar behaviour in TS/A 
cells, although the slight decrease in G2/M phase induced by DCA in our model did not appear statistically 
significant. 
Assessment of the glycolytic inhibitory effect of DCA on tumour cells has been usually carried out in vitro 
studies by measuring pHe changes. Our in vivo MRI-based observations correlate well with the in vitro 
studies as they show a significant increase in the pHe following the DCA treatment. The alkalinisation of the 
pHe was even more pronounced when TS/A cells were cultured in hypoxic conditions (1% O2), simulating a 
poorly-perfused tumour microenvironment. We observed a similar shift of the deregulated metabolism in 
treated mice as earlier as three days after the application of the DCA-treatment.  
Decreased oxygen availability (hypoxia) stimulates cells to consume glucose and produce lactate. Lactate is 
taken up by surrounding tumour cells with reciprocal recycling to support the growth of the tumour and 
resistance to apoptotic cell death mechanisms (DeBerardinis et al, 2008). Other studies in breast, prostate, 
colorectal cancer cell lines showed that lactate production is reduced upon DCA treatment (Kailavasan et al, 
2014; Lefort et al, 2014; Lin et al, 2014; Robey & Martin, 2011; Xintaropoulou et al, 2015). We observed a 
similar decrease in lactate levels after three days of treatment. Notably, these changes in lactate levels were 
correlated with changes in tumour pHe. Treated mice showed lower lactate levels and lower acidification 
after 3 days of treatment as compared to untreated mice. 
Interestingly, despite DCA treated mice showed a limited tumour growth following 15 days of treatment, 
only a slight increase of the survival time was observed as compared to untreated mice. It is known that DCA 
alone has a moderate efficiency as chemotherapeutic drug, as its antineoplastic pharmacological effect can be 
augmented when used in combination with other drugs (Haugrud et al, 2014; Robey & Martin, 2011; 
Sanchez et al, 2013; Stander et al, 2015). Our results are in agreement with these observations, as similar 
lactate levels were observed in untreated and treated mice after 15 days of treatment. These results parallel 
those obtained by measuring in vivo tumour pHe, which at 15 days show a reduced difference between 
treated and untreated mice in terms of pHe changes and of acidity scores. These findings confirm the ability 
of the proposed non-invasive approach to assess the onset of resistance to DCA, since tumour acidosis, 
despite significantly reduced after 3 days of treatment, returned to almost baseline values after 15 days. This 
behaviour was confirmed by similar changes in lactate levels. Moreover, the inefficacy of DCA to halt 
tumour glycolysis after 15 days, as measured by the proposed approach, anticipated the lack of difference in 
terms of survival times between treated and untreated groups.  
In this study, in vivo pH changes were assessed by MRI-CEST imaging using iopamidol, a MRI-CEST pH-
responsive agents able to map pHe and tumour perfusion in the microenvironment in which it distributes 
(Anemone et al, 2016; Longo et al, 2016b; Longo et al, 2014). Although iopamidol showed a heterogeneous 
distribution in the tumour region, the application of the ratiometric pH method allowed obtaining 
representative pH maps for the region of interest. To get more insight into the tumour pHe heterogeneity we 
calculated the acidity score that reports on the distribution of pixels aggregated on the basis of their relative 
acidity inside the tumour region. Representative treated mice acidity score maps showed an increase in blue 
pixel during DCA treatment, reflecting the DCA-induced glycolysis inhibition, hence alkalinisation of 
tumour pHe. A similar decrease of tumour acidosis was observed in a xenograft model of B-cell lymphoma 
upon treatment with metaiodobenzylguanidine by using an analogous pH-responsive CEST agent (Chen et 
al, 2015). Interestingly, also endogenous CEST pH mapping allows to monitor intracellular acidification 
following Lonidamine or Topiramate treatment in orthotopic glyoblastoma tumors (Marathe et al, 2016; 
McVicar et al, 2015). All these results confirm the feasibility of MRI-CEST pH mapping to monitor the 
response to drugs targeting tumour metabolism. 
In conclusion, this study demonstrated that MRI-CEST pH imaging is able to detect the early therapeutic 
response to DCA by measuring changes in tumour pHe that correlate well with the observed reduced lactate 
levels as a consequence of the reversed glycolytic phenotype. These results suggest that MRI-CEST pH 
imaging may serve as a useful imaging biomarker for monitoring treatment response to drugs targeting 
tumour deregulated glycolysis. 
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Titles and legends to figures 
 
Figure1. Effect of DCA on cell growth. (A and B) Percentage of vitality of TS/A (A) and J774 (B) cells 
after 24 hours of DCA treatment. (C and D) extracellular pH measurement after 24 hours of DCA treatment 
for TS/A cells grown in normoxic (C) or in hypoxic (D; 1% O2) conditions. *P < 0.05; ***P < 0.0001, 
Dunnett's Multiple Comparison Test. 
Figure2. Effect of DCA on tumour growth in vivo. (A) Normalised and (B) delta volume % of TS/A tumour 
bearing mice before and after 3 or 15 days of DCA treatment. (C) Mice survival curve after DCA treatment. 
Figure3. Tumour pHe (A) and acidity score (B) changes calculated from TS/A tumour bearing mice upon 
DCA treatment after 3 and 15 days, in comparison to before treatment tumour pHe values for untreated and 
treated mice. (C) Lactate quantification from excised TS/A tumour tissues for untreated and treated mice 
after3 days and 15 days of DCA treatment. (D) Correlation between changes in tumour pHe and normalised 
lactate concentration (Pearson r = -0,97). 
Figure 4. Representative tumour pHe maps superimposed on anatomical images at baseline (top right), 3 
days (bottom left) and 15 days (bottom right) post DCA treatment for untreated (A) and treated mouse (B). 
Figure 5. Representative tumour extracellular acidty maps at baseline (top right), 3 days (bottom left) and 15 
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